Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema

Tiosano, Liran; Ayalon, Anfisa; Banin, Eyal; Averbukh, Edward; Jaouni, Tareq; Chowers, Itay

doi:10.1080/02713683.2020.1812085

Cited by 1 publication

(5 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We recently reported the outcome of second-line anti-VEGF treatment in bilateral DME. 11 In that study, a correlation of treatment outcome between fellow eyes was found under first- (bevacizumab) and second-line (Ranibizumab) therapies. Unlike the current study, all eyes included in our previous report failed to show sufficient response to first-line bevacizumab.…”

Section: Discussionmentioning

confidence: 91%

“…13 There are several potential underlying factors for the correlation identified between the responses of both eyes when treated with ranibizumab but not when treated with the bevacizumab. 9,11 This finding may reflect chance, as the study groups in each of the reports were limited in size. Yet, it is also plausible that differences in compound efficacy may underlie this finding.…”

Section: Discussionmentioning

confidence: 99%

“…The fact that this study showed similar results to our previous report may indicate that under ranibizumab therapy, similar response of fellow eyes may be expected. 11…”

Section: Discussionmentioning

confidence: 99%

“…The fact that this study showed similar results to our previous report may indicate that under ranibizumab therapy, similar response of fellow eyes may be expected. 11 Karth et al 10 evaluated 56 DME eyes (n = 28 subjects) and assessed the response to IVB for the SE based on the response in the FE. The authors reported a correlation in central subfield thickness in OCT after only one injection with IVB between the eyes.…”

Section: Discussionmentioning

confidence: 99%

“…8 Although bilateral treatment for DME is common, there are limited data regarding the correlation of treatment outcome between fellow eyes of the same individual. [9][10][11] If application of a compound failed to obtain reduction of DME in the first treated eye in an individual with bilateral DME, it may be reasonable to predict that initiating treatment for the second eye using the same compound will be futile. This study was conducted in order to assess the possibility that the outcome of bevacizumab therapy in the first treated eye in cases of bilateral DME may predict the outcome in the fellow eye.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Correlation of response to intravitreal bevacizumab treatment between the first and second treated eyes in diabetic macular edema

Levinger

Tiosano

Assayag

et al. 2021

European Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Purpose To evaluate whether outcome of bevacizumab treatment in the first treated eye can guide the selection of compound for the second treated eye in patients with bilateral diabetic macular edema. Methods Demographic, clinical, and optical coherence tomography data were retrospectively collected from consecutive patients who underwent bevacizumab therapy for bilateral diabetic macular edema. Change in central subfield thickness and visual acuity were evaluated and compared between the first treated eye and second treated eye. Results A total of 66 eyes of 33 patients were included in the study. The mean ± SD follow-up time was 13 ± 5 months. The mean ± SD central subfield thickness at baseline was 464 ± 30 μm in the first treated eye and 461 ± 29 μm in the second treated eye ( p = 0.91). Final central subfield thickness was reduced to 392 ± 27 μm in the first treated eye ( p = 0.01 compared with baseline) and 416 ± 25 μm in the second treated eye ( p = 0.03 compared with baseline). Using ≥5% or ≥10% reduction of central subfield thickness as diagnostic criteria to predict similar magnitude of thickness reduction in the first treated eye yielded a positive and negative predictive value ranging from 46% to 81%, and sensitivity and specificity ranging from 54% to 84%. Regression models did not show correlation between central subfield thickness reduction in first treated eye and the second treated eye at the end of follow-up. Conclusions Bevacizumab therapy reduced macular thickness in both eyes in bilateral diabetic macular edema. Treatment outcome of the first treated eye could not predict the outcome of the second treated eye. Particularly, failure to reduce central subfield thickness in the first treated eye does not preclude a favorable response to bevacizumab therapy in the second eye.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 99%

“…The fact that this study showed similar results to our previous report may indicate that under ranibizumab therapy, similar response of fellow eyes may be expected. 11…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations